GSK3B and dementia: Mechanistically, it has been proposed that during AD and related dementias, GSK3β activity may become deregulated due to its increased expression or as a result of alterations in upstream regulators of GSK3β, leading to enhancement of NMDAr-LTD and neurodegeneration [18].